Copart Hovers at Nasdaq-100 Exit Line with Buybacks at Record High

CPRT has spent the week in an unusual bind: its shares gained 4% but remain close enough to a critical index threshold that a single bad week could trigger $2.4 billion of forced selling, even as the company's own buyback program is running at the highest pace in its history.

The index pressure is the most concrete near-term mechanical risk on the stock. ORTEX puts the probability of Copart being deleted from the Nasdaq-100 at the December 2026 Annual Review at 47%. The stock closed Friday at $29.00. The price that flips the index rule against Copart is $29.63, just 2.2% above the close. Rank is determined on November 30. If deletion is confirmed, the announcement lands December 11 with the trade settling December 21, and index trackers would need to sell the equivalent of 7.4 days of normal volume. Across 19 comparable deletions, 79% of names moved in the expected direction from announcement to effective date, with a median move of negative 3.5%. Those are historical observations, not a forecast for this one.

Positioning offers no clear lean in either direction. Short interest is modest at 3.1% of free float, up about 3% on the week but down more than 20% over the past month. The borrowing market is extraordinarily loose: availability is essentially uncapped, with around 795 million shares available to borrow against a short position of roughly 30 million. Cost to borrow has crept up 30% on the week to 0.54%, but the absolute level remains negligible. Options tell a more interesting story. The put/call ratio fell to 0.41 on Thursday, nearly two standard deviations below its 20-day average of 0.50. That is the most call-skewed reading of the past year, suggesting traders are buying into the week's rally rather than hedging against further declines. Short interest and the borrow market frame a low-conviction short position; options suggest the marginal buyer is active.

The Street is modestly constructive but not unanimous. Most recent analyst moves following the September earnings print were mixed. JP Morgan upgraded to Overweight with a $40 target after the results, while HSBC moved the other way, downgrading to Hold with a $36 target. BNP Paribas reiterated Outperform and lifted its target to $43. Barclays remains the outlier on the bear side, carrying an Underweight with a $25 target. The mean target across the analyst base is $39, implying roughly 34% upside to the current price. The bull case rests on global average selling prices rising 5.6% in the most recent quarter and international buyers now accounting for 38% of auction units. The bear case centres on depressed unit growth and softening gross transaction values. At a PE of 16.4x and EV/EBITDA of 10.2x, the valuation has compressed, down from the elevated multiples the stock commanded during its strong run. Among factor scores, Copart ranks in the 88th percentile on sector relative strength but only the 45th on short score, consistent with a stock that screens well operationally but carries real price momentum baggage.

The most striking data point sits in Copart's own corporate filings. The company repurchased $1.41 billion of its own shares in the quarter ending April 2026, the largest Q2 buyback spend on record going back to 2010 and the highest quarterly figure since the series began in 2009. That commitment is happening into a stock that has fallen roughly 30% year-to-date. The buyback history does not constitute an earnings lead under ORTEX's measured methodology, but the scale and timing are worth noting alongside the index rebalance risk: the company itself has been one of the larger buyers of the stock, at prices well above current levels.

Insider flows add a layer of nuance. Director Diane Morefield sold 20,000 shares on October 15 at $27.66 in a discretionary transaction, not under a 10b5-1 plan. The 90-day net insider position is a modest negative, reflecting the CEO's planned option-exercise-and-sell activity in July under a pre-arranged 10b5-1 program, which carries far less signal than a discretionary trade. The Chairman's October 9 transfer transaction involved 3.09 million shares but appears to be a gift or restructuring rather than an open-market sale, given the null price and matched buy/sell entries. The cleaner read from the recent filing history is cautious rather than alarmed: no large discretionary open-market purchases, and a small discretionary sale from a director.

With earnings due November 19, the November 30 index rank date lands nine days after the print, meaning the Q1 fiscal 2027 results will directly shape where the stock sits when the Nasdaq-100 eligibility calculation is made.